- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion -

Two oral presentations of phase 2 study findings from novel treatment options: an all-oral decitabine-cedazuridine combination for AML and zipalertinib

ALBANY, Ga., April 23, 2025 /PRNewswire/ -- Research from the University of Barcelona and CIBEROBN indicates that the consumption of

Megha Engineering & Infrastructure Ltd (MEIL) has secured a significant order worth ₹13,000 crore from the Nuclear Power Corporation of

With this new order of 378 MW, Suzlon reinforces its position as a key driver of India’s renewable energy transition.